Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

  • Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1]
  • Ziextenzo is indicated to reduce duration of neutropenia / incidence of febrile neutropenia, some of the most serious side effects of chemotherapy [2]
  • Sandoz demonstrates commitment to making access happen for patients with eight biosimilars approved in EU, including five in last 18 months

Holzkirchen, November 27, 2018 – Sandoz, a Novartis division …

/by